Skip to main content

idiopathic pulmonary fibrosis Archives

New target for lung fibrosis

Oct. 20, 2022—Blocking thromboxane-prostanoid receptor signaling protected animals from lung fibrosis in preclinical models, suggesting a new treatment for IPF — a chronic, progressive lung disorder that often kills within 3-5 years of diagnosis.

Read more


VUMC and TGen receive $6.1 million in grants to study deadly lung disease

Mar. 27, 2019—Vanderbilt University Medical Center, the Translational Genomics Research Institute (TGen), an affiliate of City of Hope and the Norton Thoracic Institute at St. Joseph’s Hospital and Medical Center in Arizona, have received a $3.5 million federal grant to study the cause of idiopathic pulmonary fibrosis (IPF) the nation’s most common and severe form of fibrotic lung disease.

Read more


Lung diseases share molecular signature

Apr. 5, 2018—Lung diseases of infancy and aging share a molecular signature, pointing to a potential target for treatment and prevention.

Read more


Study tracks therapy to slow idiopathic pulmonary fibrosis

Feb. 1, 2018—Investigators in the Division of Allergy, Pulmonary and Critical Care have launched a pilot study to see if patients with idiopathic pulmonary fibrosis (IPF) can tolerate the addition of a commonly used antiviral drug to standard IPF treatments. The research team believes the drug may ultimately help slow progression of the chronic and progressive disease or reverse its course.

Read more


Major grant enhances pulmonary fibrosis research

Aug. 18, 2016—Vanderbilt University Medical Center (VUMC) has received an $11 million program project renewal grant from the National Heart, Lung and Blood Institute to study the genetics and underlying biological mechanisms that lead to idiopathic pulmonary fibrosis (IPF).

Read more


New drugs approved to fight idiopathic pulmonary fibrosis

Jan. 15, 2015—The Vanderbilt Idiopathic Pulmonary Fibrosis Center played a key role in testing the first two drugs approved by the FDA for the treatment of idiopathic pulmonary fibrosis (IPF).

Read more


Lung damage protector

Apr. 12, 2013—Targeting repair pathways in the lung’s air sacs may be a valuable therapeutic direction for pulmonary fibrosis – the scarring of lung tissue.

Read more


Study examines sleep apnea’s role in lung diseases

Apr. 13, 2012—Vanderbilt’s idiopathic pulmonary fibrosis research group is embarking on a study to determine the prevalence of sleep apnea in people with other interstitial lung diseases.

Read more


Lung disorder drug regimen found harmful

Oct. 31, 2011—Longtime treatment for IPF ineffective and even dangerous.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more